옵션 체인은 다양한 행사가격과 만기일에 대한 Aptose Biosciences의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Aptose Biosciences에 대한 시장 심리를 평가합니다..

Aptose Biosciences (NASDAQ:APTO) 주식, 옵션 체인

Aptose Biosciences

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

APTO

MOMO

SPWH

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 헬로 그룹(NASDAQ:MOMO)이 개장 전에 3억 7,252만 달러의 매출과 주당 28센트의 분기 이익을 보고할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 헬로 그룹의 주가는 시간외 거래에서 0.6% 하락한 6.60달러를 기록했다.

화요일 주목해야 할 주식: 헬로 그룹, Z스케일러, 앱토즈 그리고 2종목

Aptose Biosciences Inc

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

Aptos - United States dollar

Shares of Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) rose sharply in today's pre-market trading after the company announced it has entered into a definitive agreement for a strategic <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know">investment of $775 million from Tether</a>.
Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) has agreed to purchase 103.33 million shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble.
Rumble shares jumped 43.3% to $10.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) gained 234% to $4.01 in pre-market trading.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) gained 88.6% to $3.32 in pre-market trading. Phio Pharmaceuticals, last week, announced a $1.15 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 82.3% to $0.4334 in pre-market trading after surging 63% on Friday. Edible Garden recently announced it experienced a 51% year-over-year increase in its preliminary Thanksgiving period sales.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) gained 60.9% to $0.8530 in pre-market trading. JIADE received Nasdaq notification letter regarding minimum bid price deficiency.</li>
<li>American Battery Technology Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>) rose 44.1% to $1.60 in pre-market trading. On Friday, American Battery Technology priced its $5 million registered direct offering of 5 million shares at $1.00 per share.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 30.9% to $3.60 in pre-market trading after jumping more than 36% on Friday.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) rose 28.8% to $0.9700 in pre-market trading after the company was awarded ISO/IEC 27001:2022 certification.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) gained 18% to $28.19 in pre-market trading. Honda Motor and Nissan Motor Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) have started talks for a potential merger.</li>
<li>Kodiak Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) rose 14.9% to $9.94 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares tumbled 28.9% to $0.0531 in pre-market trading after jumping 14% on Friday. Conduit Pharmaceuticals recently announced it entered an agreement with Sarborg to leverage AI and its cybernetics platform to evaluate key deliverables across multiple areas of operations.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) declined 25.7% to $0.6759 in pre-market trading after jumping around 101% on Friday.</li>
<li>Onfolio Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) fell 24.4% to $1.21 in pre-market trading. Onfolio Holdings announced a quarterly preferred stock cash dividend of 75 cents per share.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares fell 24.3% to $0.6703 in pre-market trading after declining 9% on Friday.</li>
<li>ConnectM Technology Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares dipped 20% to $0.83 in pre-market trading after falling 8% on Friday. ConnectM Technology Solutions, last week, announced a year-over-year increase in third-quarter revenue results.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) fell 19.2% to $1.94 in today's pre-market trading after jumping 97% on Friday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) dipped 17.8% to $0.2293 in pre-market trading after jumping 64% on Friday. Aptose Biosciences, last week, announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) fell 11% to $15.00 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares fell 10.8% to $8.53 in pre-market trading.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) fell 8.5% to $5.41 in pre-market trading.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Movers

$USDT

ABAT

AILE

ATXS

BNRG

CNTM

EDBL

HSDT

JDZG

LAES

NSANY

ONFO

PHIO

RELI

SIGA

TPIC

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Shares of FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) rose sharply in today's pre-market trading as the company posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/24/12/42605034/fedex-stock-rallies-on-better-than-expected-q2-eps-freight-spin-off-announcement">results for its second quarter</a>.
The company also announced that it has decided to pursue a full separation of FedEx Freight through the capital markets, creating a new publicly traded company.
FedEx shares jumped 8.7% to $299.80 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) gained 80.5% to $0.3070 in pre-market trading after the company announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) gained 67.4% to $4.12 in pre-market trading fater jumping more than 60% on Thursday. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.</li>
<li>Ocean Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) climbed 62.5% to $0.9576 in pre-market trading.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) gained 52.8% to $4.08 in pre-market trading after jumping 317% on Thursday.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) rose 44.5% to $5.00 in pre-market trading as the company announced the FDA approval of SYMVESS&#x2122; (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma.</li>
<li>Aadi Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AADI#NASDAQ">AADI</a>) gained 35.3% to $3.14 in pre-market trading after the company secured $100 million PIPE financing and announced the sale of FYARRO for $100 million.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) gained 26.9% to $1.19 in pre-market trading after the company announced 7.85 million of its shares was acquired by Gilead Sciences.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) rose 17.4% to $8.78 in pre-market trading after dipping over 12% on Thursday.</li>
<li>Clearwater Paper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) gained 11.8% to $27.62 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares tumbled 49.5% to $0.1785 in pre-market trading after the company announced notice of delisting and failure to satisfy continued listing rules.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) declined 36.4% to $7.10 in pre-market trading after jumping around 410% on Thursday.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares fell 26.7% to $0.2998 in pre-market trading after jumping 56% on Thursday. Cara Therapeutics recently announced it entered into an all-stock merger with Tvardi Therapeutics.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) fell 25.8% to $76.80 in pre-market trading. Novo Nordisk said CagriSema demonstrated weight loss in adults with obesity or overweight in the REDEFINE 1 trial.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares dipped 25.2% to $0.9730 in pre-market trading after climbing 65% on Thursday.</li>
<li>Mobix Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) fell 24.5% to $1.57 in today's pre-market trading after reporting third-quarter results.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) dipped 23.6% to $1.94 in pre-market trading. Zoomcar said it launched Zoomcar Cabs, which are affordable car rentals with drivers as a new offering.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 18.1% to $13.72 in pre-market trading. Mesoblast shares jumped over 36% on Thursday after the company announced the FDA approved Ryoncilas the first mesenchymal stromal cell therapy in the United States.</li>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) fell 13.1% to $8.66 in pre-market trading after jumping over 52% on Thursday.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 11.1% to $13.46 in pre-market trading after declining 41% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42609619/sp-500-nasdaq-end-in-red-as-investor-sentiment-declines-micron-tumbles-after-sales-miss-greed-index-in-extreme-fear-zone">S&amp;P 500, Nasdaq End In Red As Investor Sentiment Declines, Micron Tumbles After Sales Miss: Greed Index In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

AADI

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

WIIM

Aptose Biosciences shares are trading higher after the company announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.

Aptose Granted Extension To Evidence Compliance For Continued Nasdaq Listing

<ul>
<li>Peer-reviewed publication details unique TUS mechanism of action</li>
<li>TUS+VEN combination synthetic lethality overcomes resistance to VEN</li>
<li>Tuspetinib prolongs survival in multiple AML models resistant to other drugs</li>
<li>Findings suggest TUS will demonstrate broad antileukemic activity across AML patients</li>
<li>TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling &nbsp;</li>
</ul>
SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/APS#TSX">APS</a>),&nbsp;a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the publication of preclinical data for Aptose's lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR), available online now <a href="https://www.globenewswire.com/Tracker?data=6GBl8ym_R-ACo5nmGwmA3uqfDC8WGgqZFivYslmwNreUH3XAZ6b6f04HoZ3sIYZLF5CIl3Yd7hrQPAiCCRT8PWidZLHvElTg2803kQqPd7PiQ3TJDi5vMGSxmchZbZGmSHlNqxvl_YmsbuW-s0EyceOn0xTonXJojGjgOFTHpju7M1Ytmk-640fsBEcaj4XNKjexVh5CCLsHNhBiNHD21sBD9gGzlACDF5y-mGCC3Dg=">(link)</a>.
The publication, entitled&nbsp;"Preclinical development of tuspetinib for the treatment of acute myeloid leukemia,"&nbsp;is the first preclinical profiling of tuspetinib, a well-tolerated, once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML). The publication defines TUS activities on select oncogenic signaling targets, demonstrates enhanced activity and safety of TUS when combined with other agents, and illustrates synthetic lethality when combined with venetoclax (VEN). Pharmacokinetic and toxicology studies revealed that TUS is readily absorbed and achieves plasma concentrations sufficient to inhibit the target kinases, it has a plasma half-life that supports once daily dosing, and it demonstrates a favorable safety profile.
Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib + venetoclax + azacitidine (TUS+VEN+AZA) triplet combination (NCT03850574). Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or the TUS+VEN combination have been completed.

Biotech

General

TSX:APS

Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To Other Drugs; Findings Suggest TUS Will Demonstrate Broad Antileukemic Activity Across AML Patients

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and maintains $2 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target

Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish Mutation-Agnostic Standard Of Care For Chemotherapy-Ineligible Patients

<ul>
<li>Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations &nbsp;</li>
<li>Trials to test tuspetinib in targeted drug combinations for frontline therapy of molecularly defined sub-groups of newly diagnosed AML and MDS</li>
</ul>

Aptose Signs CRADA With National Cancer Institute To Develop Tuspetinib For AML And MDS In Precision Medicine Trials

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8M public offering.

Shares of Uxin Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NYSE">UXIN</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/UXIN/earnings">second-quarter financial results.</a>
Uxin posted quarterly sales of $70.85 million, up from $48.80 million in the year-ago period
Uxin shares rose 3% to $6.50 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 59.2% to $2.77 in pre-market trading after climbing around 18% on Friday.</li>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) rose 40.4% to $12.84 in pre-market trading after jumping 127% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) gained 29.8% to $0.5777 in pre-market trading after gaining around 7% on Friday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 28.4% to $23.59 in pre-market trading after jumping around 69% on Friday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) gained 22% to $15.76 in pre-market trading after gaining 21% on Friday.</li>
<li>NOVONIX Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) gained 19.1% to $2.31 in pre-market trading. Novonix secured a 32,000-tonne offtake agreement with Volkswagen&#8217;s PowerCo for synthetic graphite supply.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 16.9% to $7.13 in pre-market trading after jumping 28% on Friday.  </li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) climbed 16.7% to $4.94 in pre-market trading. Allot, last week, reported better-than-expected quarterly financial results.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) gained 11.2% to $7.89 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Akoustis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) shares tumbled 37.5% to $0.0629 in pre-market trading</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 17.8% to $0.1560 in pre-market trading. Aptose Biosciences shares dipped 22% on Friday after the company announced the pricing of an $8 million public offering.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) declined 16.6% to $1.76 in pre-market trading.</li>
<li>NewGenIvf Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) fell 16.1% to $0.43 in pre-market trading after declining 6% on Friday.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) fell 13.9% to $0.0173 in pre-market trading. Elevai Labs implemented a 1-for-200 reverse stock split to retain Nasdaq listing, reducing shares to 3.07 million.</li>
<li>Gold Resource Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GORO#NYSE">GORO</a>) shares fell 13.1% to $0.1368 in pre-market trading after gaining 6% on Friday.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) dipped 12.4% to $0.1063 in pre-market trading after falling over 4% on Friday.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 6.9% to $22.15 in pre-market trading. ZIM Integrated Shipping Services, last week, reported better-than-expected third-quarter financial results and raised its FY24 adjusted EBIT and EBITDA guidance.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) fell 5.9% to $7.00 in pre-market trading.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) fell 4.3% to $6.90 in today's pre-market trading after jumping around 25% on Friday. Kingsoft Cloud, last week, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

AKTS

ALLT

ARQQ

CDXC

DBGI

ELAB

GORO

KULR

LION

NIVF

Nuveen California Dividend Advantage Municipal Fund 2

QMCO

RGTI

UXIN

XCUR

XTKG

Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining by more than 350 points on Friday.
The Dow traded up 0.82% to 44,228.50 while the NASDAQ rose 0.14% to 18,998.27. The S&amp;P 500 also rose, gaining, 0.31% to 5,966.91.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1.5% on Friday.
In trading on Friday, communication services shares fell by 0.6%.
Top Headline
Shares of Intuit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell over 5% on Friday after the company reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.
The company reported quarterly earnings of $2.50 per share, which beat the analyst consensus estimate of $2.35 per share. Quarterly revenue came in at $3.28 billion which beat the consensus estimate of $3.14 billion
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares shot up 16% to $109.17 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Shares of Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) got a boost, surging 19% to $30.26 following upbeat earnings.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 45% to $16.00 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 55% to $6.11 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 43% to $0.1390 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 41% to $0.1164 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $71.16 while gold traded up 1.1% at $2,704.00.
Silver traded up 1.1% to $31.275 on Friday, while copper fell 0.8% to $4.0940.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.12%, Germany's DAX gained 0.77% and France's CAC 40 rose 0.46%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 gained 1.35%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a>

AMIX

CETX

ESTC

INTU

MATW

REPL

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining by more than 250 points on Friday.
The Dow traded up 0.59% to 44,128.84 while the NASDAQ rose 0.08% to 18,986.80. The S&amp;P 500 also rose, gaining, 0.28% to 5,965.15.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1.5% on Friday.
In trading on Friday, communication services shares fell by 0.6%.
Top Headline
Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) reported better-than-expected third-quarter EPS results.
The company said it sees FY25 earnings of $6.10 to $6.17 per share
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares shot up 16% to $109.17 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Shares of Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) got a boost, surging 19% to $30.26 following upbeat earnings.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 45% to $16.00 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 55% to $6.11 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 43% to $0.1390 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 41% to $0.1164 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $71.16 while gold traded up 1.1% at $2,704.00.
Silver traded up 1.1% to $31.275 on Friday, while copper fell 0.8% to $4.0940.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.12%, Germany's DAX gained 0.77% and France's CAC 40 rose 0.46%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 gained 1.35%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

ROST

Crude Oil Gains Over 1%; Ross Stores Earnings Top Views

U.S. stocks traded higher this morning, with the Dow Jones index gaining by more than 300 points on Friday.
Following the market opening Friday, the Dow traded up 0.72% to 44,184.62 while the NASDAQ rose 0.07% to 18,985.33. The S&amp;P 500 also rose, gaining, 0.35% to 5,969.29.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1% on Friday.
In trading on Friday, communication services shares fell by 0.4%.
Top Headline
Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported better-than-expected earnings for its second quarter and raised its outlook for FY24 gross margin.
&nbsp;The company reported quarterly earnings of 54 cents per share, which beat the analyst consensus estimate of 40 cents per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) shares shot up 76% to $1.95 after declining around 75% on Wednesday.</li>
<li>Shares of DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) got a boost, surging 77% to $0.8931.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 48% to $16.37 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 52% to $6.53 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 44% to $0.1374 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 42% to $0.1148 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $70.67 while gold traded up 0.9% at $2,697.70.
Silver traded up 1.2% to $31.33 on Thursday, while copper fell 0.8% to $4.0910.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.2%, Germany's DAX gained 0.9% and France's CAC 40 rose 0.7%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 gained 1.4%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

DEVS

Dow Jumps 300 Points; Gap Posts Upbeat Earnings

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8 million public offering.

Offerings

Aptose Biosciences Prices $8M Public Offering Of 40M Shares And 20M Warrants At $0.20 Per Unit; Warrants Priced At $0.25 Per Share And Expire In Five Years, With Closing Expected On November 25, 2024

Shares of Elastic N.V (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY25 guidance <a href="https://www.benzinga.com/quote/ESTC/news">above estimates</a>.
Elastic reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 38 cents per share. The company reported quarterly sales of $365.361 million which beat the analyst consensus estimate of $355.900 million.
Elastic shares jumped 29.1% to $121.46 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) gained 67.1% to $0.9855 in pre-market trading after the company announced an agreement with the US HHS department for an extension towards its cooperative research and development.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 50.4% to $1.88 in pre-market trading after dipping 62% on Thursday.</li>
<li>Beneficient  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) gained 30.7% to $1.15 in pre-market trading after gaining around 7% on Thursday.</li>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) gained 25.4% to $1.38 in pre-market trading after declining around 75% on Wednesday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 19.4% to $12.98 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) gained 14.9% to $25.33 in pre-market trading after reporting better-than-expected third-quarter results.</li>
<li>Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) gained 10.4% to $6.90 in pre-market trading.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) climbed 8.7% to $1.63 in pre-market trading.</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) gained 7% to $153.01 in pre-market trading after the company reported better-than-expected third-quarter EPS results..</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares tumbled 41.8% to $10.64 in pre-market trading after the company announced the pricing of $12.1 million public offering.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) fell 33.3% to $9.01 in pre-market trading.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 27.2% to $0.1430 in pre-market trading after the company announced its board approved a 1-for-35 reverse stock split.</li>
<li>Procaps Group S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) declined 18.7% to $0.90 in pre-market trading as the company said it faced Nasdaq delisting threat due to Form 20-F filing delay.</li>
<li>Carter Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) shares fell 10.6% to $16.86 in pre-market trading.</li>
<li>Real Messenger Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMSG#NASDAQ">RMSG</a>) dipped 16.2% to $3.51 in pre-market trading after jumping over 10% on Thursday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) fell 13.9% to $0.21 in pre-market trading after dipping more than 10% on Thursday.</li>
<li>Envoy Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares dipped 12.7% to $1.92 in pre-market trading.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.3% to $146.50 in pre-market trading. Reddit's shareholder, Advance Magazine Publishers Inc. plans to sell as much as $1.2 billion of the company's stake, reported Bloomberg on Friday morning. The company is said to be offering 7.8 million shares in between the range of $145.38-$148.54 each.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell 5.7% to $639.95 in today's pre-market trading. Intuit reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>

BENF

CARE

Envoy Medical, Inc. - Class A Common Stock

COCH

KAPA

KSCP

PROC

RDDT

RMSG

VRPX

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and lowers the price target from $7 to $2.

HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Lowers Price Target to $2

Aptose Biosciences Announced Initiation Of The TUSCANY Study, Tuspetinib In Combination Therapy With Azacitidine And Venetoclax As A Frontline Triplet Combination Therapy For Patients Newly Diagnosed With Acute Myeloid Leukemia

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(1.19) by 68.91 percent.

Earnings Beats

Aptose Biosciences Q3 2024 GAAP EPS $(0.37) Beats $(1.19) Estimate

Aptose Biosciences ( ($TSE:APS) ) has provided an announcement. Aptose Biosciences Inc., a Canadian company specializing in precision oncology, has...

Aptose Biosciences Boosts Capital with $8M Offering

Aptose Biosciences (APTO) announced that the National Cancer Institute, NCI, part of the National Institutes of Health, and Aptose Biosciences Inc....

Aptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDS

Aptose Biosciences (APTO) featured a wealth of clinical data for Aptose's lead compound tuspetinib in a poster presentation at the 66th American So...

Aptose Biosciences announces clinical data on tuspetinib

The latest update is out from Aptose Biosciences ( ($TSE:APS) ). Aptose Biosciences is advancing tuspetinib (TUS), a promising oral kinase inhibito...

Aptose Biosciences Advances TUS as AML Therapy

Aptose Biosciences (APTO) announced the publication of preclinical data for Aptose's lead hematology compound tuspetinib in Cancer Research Communi...

Aptose Biosciences announces publication of preclinical data on tuspetinib

Aptose Biosciences ( ($TSE:APS) ) has shared an announcement. Aptose Biosciences announced the publication of preclinical data on its lead compound...

Aptose Biosciences Publishes Promising Preclinical Data on Tuspetinib

Aptose Biosciences (APTO) announced that Nasdaq has granted the company's request for an extension to evidence compliance with all applicable crite...

Aptose Biosciences granted extension to regain compliance with Nasdaq

Aptose gets Nasdaq extension to regain compliance

An update from Aptose Biosciences ( ($TSE:APS) ) is now available. Aptose Biosciences announced that the Nasdaq Hearings Panel has granted an exten...

Aptose Biosciences Granted Nasdaq Compliance Extension

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

GALT

ONCY

Financing

Press Releases

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Announces Results from Special Meeting of Shareholders

Aptose Reports Results for the Third Quarter 2024

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Health Care

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Comments

Aptose Biosciences

Aptose Biosciences (APTO) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌